Evidence map›Paper›PMID 39082680›Full record

ArticleCancer research2024

A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis.

Brian S White, Xing Yi Woo, Soner Koc, Todd Sheridan, Steven B Neuhauser, Shidan Wang, Yvonne A Evrard, Li Chen, Ali Foroughi Pour, John D Landua and 45 more

Abstract read
In one paragraph

Article in Cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

55 authors.

Brian S WhiteThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.ORCID 0000-0002-2954-4410
Xing Yi WooThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.ORCID 0000-0002-5980-4383
Soner KocVelsera, Charlestown, Massachusetts.ORCID 0000-0002-0772-6600
Todd SheridanThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.ORCID 0000-0001-8968-9315
Steven B NeuhauserThe Jackson Laboratory, Bar Harbor, Maine.ORCID 0000-0002-2993-9324
Shidan WangUniversity of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-0001-3261
Yvonne A EvrardLeidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.ORCID 0000-0002-3475-4850
Li ChenLeidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.ORCID 0000-0001-7973-5912
Ali Foroughi PourThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.ORCID 0000-0002-3547-0796
John D LanduaBaylor College of Medicine, Houston, Texas.ORCID 0000-0002-4747-3038
R Jay MashlWashington University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-0365-8954
Sherri R DaviesWashington University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-7141-8354
Bingliang FangUniversity of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-9225-3010
Maria Gabriela RasoUniversity of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-2105-5556
Kurt W EvansUniversity of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0008-6823-6809
Matthew H BaileySimmons Center for Cancer Research, Brigham Young University, Provo, Utah.ORCID 0000-0003-4526-9727
Yeqing ChenThe Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0002-5602-3311
Min XiaoThe Wistar Institute, Philadelphia, Pennsylvania.ORCID 0009-0005-1667-5146
Jill C RubinsteinThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.ORCID 0000-0002-1222-8657
Brian J SandersonThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.ORCID 0000-0002-0310-0440
Michael W LloydThe Jackson Laboratory, Bar Harbor, Maine.ORCID 0000-0003-1021-8129
Sergii DomanskyiThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.ORCID 0000-0002-6847-6019
Lacey E DobroleckiBaylor College of Medicine, Houston, Texas.ORCID 0000-0001-6839-629X
Maihi FujitaHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0003-2619-1637
Junya FujimotoUniversity of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4813-3163
Guanghua XiaoUniversity of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0001-9387-9883
Ryan C FieldsWashington University School of Medicine, St. Louis, Missouri.ORCID 0000-0001-6176-8943
Jacqueline L MuddWashington University School of Medicine, St. Louis, Missouri.ORCID 0000-0001-7618-8765
Xiaowei XuThe Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0003-4098-7690
Melinda G HollingsheadNational Cancer Institute, Bethesda, Maryland.ORCID 0000-0002-1207-1397
Shahanawaz JiwaniLeidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.ORCID 0000-0002-4717-8637
Saul AcevedoVelsera, Charlestown, Massachusetts.ORCID 0009-0006-4706-6308
PDXNet Consortium
Brandi N Davis-DusenberyVelsera, Charlestown, Massachusetts.ORCID 0000-0001-7811-8613
Peter N RobinsonThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.ORCID 0000-0002-0736-9199
Jeffrey A MoscowNational Cancer Institute, Bethesda, Maryland.ORCID 0000-0002-0479-1693
James H DoroshowNational Cancer Institute, Bethesda, Maryland.ORCID 0000-0002-4463-1790
Nicholas MitsiadesBaylor College of Medicine, Houston, Texas.ORCID 0000-0002-4659-476X
Salma KaocharBaylor College of Medicine, Houston, Texas.ORCID 0000-0001-9437-8829
Chong-Xian PanUniversity of California, Davis, Davis, California.ORCID 0000-0002-8588-3994
Luis G Carvajal-CarmonaUniversity of California, Davis, Davis, California.ORCID 0000-0001-7129-2918
Alana L WelmHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-1412-1351
Bryan E WelmHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-1879-6612
Ramaswamy GovindanWashington University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-6964-9612
Shunqiang LiWashington University School of Medicine, St. Louis, Missouri.ORCID 0000-0001-9508-7249
Michael A DaviesUniversity of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-0977-0912
Jack A RothUniversity of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-8955-1313
Funda Meric-BernstamUniversity of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-6816-6072
Yang XieUniversity of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0001-9456-1762
Meenhard HerlynThe Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0003-0839-0739
Li DingWashington University School of Medicine, St. Louis, Missouri.ORCID 0000-0003-1517-2975
Michael T LewisBaylor College of Medicine, Houston, Texas.ORCID 0000-0002-6330-4007
Carol J BultThe Jackson Laboratory, Bar Harbor, Maine.ORCID 0000-0001-9433-210X
Dennis A DeanVelsera, Charlestown, Massachusetts.ORCID 0000-0002-7621-9717
Jeffrey H ChuangThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.ORCID 0000-0002-3298-2358

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
Shared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI William Carl Skarnes · 1985 to 2026
$61.9M
Mouse Models of Human Cancer DatabaseR01CA089713 · NCI · JACKSON LABORATORY · PI BULT, CAROL J · 2002 to 2025
$17.5M
Research Project 2 - Targeting Melanoma Tumor Survival and Apoptotic MachineryU54CA224070 · NCI · WISTAR INSTITUTE · PI Jessie Villanueva · 2017 to 2026
$13.9M
Tolinapant efficacy in a subset of triple negative breast cancersU54CA224076 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Michael T. Lewis · 2017 to 2026
$13.5M
Washington University PDX Development and Trial Center - Evaluation of Abemaciclib in Combination with Olaparib in Ovarian Cancer and Breast Cancer Patient-derived Xenograft ModelsU54CA224083 · NCI · WASHINGTON UNIVERSITY · PI Brian Andrew Van Tine · 2017 to 2026
$13.0M
Targeting exosomal PDL1 to improve immunotherapyP50CA261608 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2021 to 2025
$11.3M
Washington University SPORE in Pancreatic CancerP50CA272213 · NCI · WASHINGTON UNIVERSITY · PI David G DeNardo, WILLIAM G HAWKINS · 2023 to 2026
$10.7M
PDXNet Data Commons and Coordinating CenterU24CA224067 · NCI · JACKSON LABORATORY · PI Jeffrey Hsu-Min Chuang · 2017 to 2026
$9.8M
University of Texas PDX Development and Trial CenterU54CA224065 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MERIC-BERNSTAM, FUNDA, ROTH, JACK · 2017 to 2022
$7.7M
THE RNA HELICASE EIF4A IS A THERAPEUTIC VULNERABILITY IN TRIPLE-NEGATIVE BREAST CANCERU54CA233223 · NCI · BAYLOR COLLEGE OF MEDICINE · PI MITSIADES, NICHOLAS · 2018 to 2022
$7.0M
University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health DisparitiesU54CA233306 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CARVAJAL CARMONA, LUIS GUILLERMO, CHEN, MOON SHAO-CHUANG · 2018 to 2022
$6.8M
Cancer Moonshot (Misión contra el Cáncer) U24-CA224067CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENCI NIH HHS HHSN261201400008CNCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003INCI NIH HHS P30 CA010815NCI NIH HHS P30 CA034196NCI NIH HHS P50 CA261608NCI NIH HHS P50 CA272213NCI NIH HHS R01 CA089713NCI NIH HHS R01 CA230031NCI NIH HHS U24 CA224067NCI NIH HHS U54 CA224065NCI NIH HHS U54 CA224070NCI NIH HHS U54 CA224076NCI NIH HHS U54 CA224083NCI NIH HHS U54 CA233223NCI NIH HHS U54 CA233306NCI NIH HHS U54 CA283766
6 · The paper itself

Abstract

Patient-derived xenografts (PDX) model human intra- and intertumoral heterogeneity in the context of the intact tissue of immunocompromised mice. Histologic imaging via hematoxylin and eosin (H&E) staining is routinely performed on PDX samples, which could be harnessed for computational analysis. Prior studies of large clinical H&E image repositories have shown that deep learning analysis can identify intercellular and morphologic signals correlated with disease phenotype and therapeutic response. In this study, we developed an extensive, pan-cancer repository of >1,000 PDX and paired parental tumor H&E images. These images, curated from the PDX Development and Trial Centers Research Network Consortium, had a range of associated genomic and transcriptomic data, clinical metadata, pathologic assessments of cell composition, and, in several cases, detailed pathologic annotations of neoplastic, stromal, and necrotic regions. The amenability of these images to deep learning was highlighted through three applications: (i) development of a classifier for neoplastic, stromal, and necrotic regions; (ii) development of a predictor of xenograft-transplant lymphoproliferative disorder; and (iii) application of a published predictor of microsatellite instability. Together, this PDX Development and Trial Centers Research Network image repository provides a valuable resource for controlled digital pathology analysis, both for the evaluation of technical issues and for the development of computational image-based methods that make clinical predictions based on PDX treatment studies. Significance: A pan-cancer repository of >1,000 patient-derived xenograft hematoxylin and eosin-stained images will facilitate cancer biology investigations through histopathologic analysis and contributes important model system data that expand existing human histology repositories.

Indexed as

Deep LearningNeoplasmsAnimalsGenomicsHeterograftsHumansImage Processing, Computer-AssistedLymphoproliferative DisordersMiceXenograft Model Antitumor Assays

Identifiers

PMID39082680
PMCPMC11217732

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.